U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298590) titled 'An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease' on Nov. 17.
Brief Summary: A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.
Study Start Date: Dec. 30
Study Type: INTERVENTIONAL
Condition:
IgG4 Related Disease
Intervention:
BIOLOGICAL: CD19/BCMA CAR NK
Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of CD19/BCMA CAR NK cells will infused using the dose-escalation strategy.
...